NEW YORK (GenomeWeb News) – Illumina said today that the Genome Institute of Singapore has added four of the company’s genetic sequencers to its sequencing tool shed, tripling its stock to a total of six.
GIS plans to use the new sequencing power for a variety of research projects including the study of transcriptional networks that may be linked to cancer and stem cells.
The Singapore institute will use the analyzers “across a broad array of applications,” GIS Associate Director of Genome Technology Yijun Ruan said in a statement. These include building transcriptional networks by “identifying transcription factor interactions and chromatin modifications in stem cells and cancer cells,” Ruan said, as well as characterizing genome and transcriptome variations in healthy patients and discovering new pathogens through metagenomic sequencing.
Ruan said the expansion of sequencing power is necessary for the institute to continue advancing its Pair-End-diTag technology, which GIS developed in part through grants from the National Human Genome Research Institute and the National Cancer Institute. The aim of that research was to develop the technology for human genome annotation and to identify complete fusion genes that can cause cancer in humans.
Less than a month ago, Illumina competitor Applied Bioystems said that GIS had acquired three of its SOLiD sequencing systems.
Financial terms of the agreement were not released.